Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Neuralstem (CUR) Competitors

Neuralstem logo

CUR vs. SRNE, NKGN, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, IKT, and IZTC

Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Sorrento Therapeutics (SRNE), NKGen Biotech (NKGN), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), and Invizyne Technologies (IZTC). These companies are all part of the "medical" sector.

Neuralstem vs. Its Competitors

Neuralstem (NASDAQ:CUR) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

38.3% of Neuralstem shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Neuralstem Neutral
Sorrento Therapeutics Neutral

Sorrento Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Sorrento Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuralstem-39,417.64% -170.51% -110.16%
Sorrento Therapeutics N/A N/A N/A

Neuralstem has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuralstem$260K14.05-$4.93MN/AN/A
Sorrento Therapeutics$60.32M0.05-$572.84MN/AN/A

Summary

Neuralstem beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Neuralstem News Delivered to You Automatically

Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUR vs. The Competition

MetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$3.65M$347.55M$6.23B$10.66B
Dividend YieldN/AN/A5.71%4.82%
P/E RatioN/AN/A30.2930.25
Price / Sales14.05495.53595.12134.57
Price / CashN/A22.4437.0161.44
Price / Book0.263.7412.046.60
Net Income-$4.93M-$133.30M$3.32B$276.82M

Neuralstem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUR
Neuralstem
N/A$1.74
-1.7%
N/A-52.8%$3.65M$260K0.006High Trading Volume
SRNE
Sorrento Therapeutics
1.0336 of 5 stars
$0.01
+40.0%
N/A+140.0%$3.86M$60.32M0.00800High Trading Volume
NKGN
NKGen Biotech
N/A$0.02
+100.0%
N/A-94.8%$899KN/A0.00N/A
SQZ
SQZ Biotechnologies
N/A$0.03
+7.1%
N/A+0.0%$885K$18.16M-0.011,620
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$6KN/A0.0070
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91M0.0070
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/A$0.00N/A0.0030Gap Down
PRME
Prime Medicine
3.2239 of 5 stars
$6.37
+6.3%
$8.92
+40.0%
+26.9%$857.24M$4.96M-3.11234Positive News
Gap Up
High Trading Volume
PLX
Protalix BioTherapeutics
2.1326 of 5 stars
$2.49
+5.1%
$15.00
+502.4%
+129.1%$198.53M$61.95M-19.15200Gap Up
IKT
Inhibikase Therapeutics
1.3762 of 5 stars
$1.60
-1.2%
$8.00
+400.0%
-38.9%$119.23MN/A-0.606News Coverage
Gap Up
IZTC
Invizyne Technologies
N/A$12.99
flat
N/AN/A$81.21MN/A0.0029News Coverage

Related Companies and Tools


This page (NASDAQ:CUR) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners